摘要
【目的】探讨卡瑞利珠单抗联合化疗对老年肺癌患者3年生存率的影响。【方法】选取本院收治的80例肺癌老年患者,随机分为两组,每组40例。对照组患者进行常规化疗,观察组患者在化疗的基础上行卡瑞利珠单抗治疗。比较两组患者临床疗效及治疗前后血清T淋巴细胞亚群水平、卡氏生存质量(KPS)评分;比较两组患者不良发应发生率及3年的生存情况。【结果】观察组患者客观有效率为55.00%(22/40),显著高于对照组的32.50%(13/40)(P<0.05);两组患者疾病控制率比较,差异无统计学意义(P>0.05)。两组患者治疗后CD4^(+)、CD4^(+)/CD8^(+)水平较治疗前均升高,CD8^(+)则降低(P<0.05);治疗后,观察组CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)则低于对照组(P<0.05)。治疗后,两组患者KPS评分高于同组治疗前(P<0.05),且观察组高于对照组(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。3年随访期间,观察组失访8例,死亡23例,存活9例;对照组失访6例,死亡28例,存活6例。Kaplan-Meier生存分析显示,两组存活率比较,差异无统计学意义(P>0.05)。【结论】卡瑞利珠单抗联合化疗较单一化疗方案治疗老年肺癌患者疗效显著,可提高患者免疫功能,且安全可靠。
【Objective】This study aimed to investigate the impact of carituzumab monoclonal antibody combined with chemotherapy on the three-year survival time in elderly patients with lung cancer.【Methods】Eighty elderly patients with lung cancer admitted to our hospital were randomly divided into two groups,with 40 patients in each group.The control group received conventional chemotherapy,while the observation group received carituzumab monoclonal antibody treatment on the basis of chemotherapy.The clinical efficacy,serum T lymphocyte subsets levels before and after treatment,Karnofsky performance status(KPS)score,adverse event incidence,and three-year survival were compared between the two groups.【Results】The objective response rate in the observation group was 55.00%(22/40),which was significantly higher than that in the control group 32.50%(13/40)(P<0.05).There was no significant difference in disease control rate between the two groups(P>0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in both groups increased,while CD8^(+)decreased compared to before treatment(P<0.05).after treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while CD8^(+)of the observation group was lower that of the control group(P<0.05).The KPS scores of both groups after treatment was higher than those before treatment(P<0.05);And the observation group had a higher KPS score than the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).During the 3-year follow-up period,8 patients were lost to follow-up in the observation group,while there were 23 deaths and 9 survivors.Meanwhile,in the control group,6 patients were lost to follow-up;And there were 28 deaths and 6 survivors.Kaplan-Meier survival analysis showed no significant difference in survival rates between the two groups(P>0.05).【Conclusion】Carituzumab monoclonal antibody combined with chemotherapy has better efficacy in the treatment of elderly patients with lung cancer,which improves patient immune function.And it is safe and reliable.
作者
郭宏果
刘军
程才
乔松
陆婉玲
GUO Hong-guo;LIU Jun;CHENG Cai(Department of Oncology and Hematology,Air Force 986 Hospital,Xi'an Shaanxi 710054)
出处
《医学临床研究》
CAS
2023年第7期1039-1042,共4页
Journal of Clinical Research
关键词
肺肿瘤
抗体
单克隆
治疗结果
无进展生存期
老年人
Lung Neoplasms
Antibodies,Monoclonal
Treatment Outcome
Progression-Free Survival
Aged